Abstract Elevated levels of circulating estrogens and androgens are linked to higher breast cancer risk among postmenopausal women; however, little is known about hormone levels within the breast. Hormone concentrations within the breast may not be reflected in the blood and are likely important contributors to breast carcinogenesis. We used a previously validated method to measure levels of estrone, estradiol, androstenedione, and testosterone in adipose tissue removed as part of breast excisions performed for cancer in 100 postmenopausal women (69 ER/ PR ?/? and 31 ER/PR -/-) participating in a breast cancer case-control study. We also measured the same steroid hormones, as well as estrone sulfate, and sex hormone-binding globulin (SHBG) in serum from these patients and 100 controls matched on ages at blood collection and on menopause. Overall, concentrations of serum hormones did not vary significantly between controls and cases. However, women with ER-/PR-breast cancers had lower circulating levels of all measured sex steroid hormones and higher SHBG levels than women with ER?/PR? breast cancers and controls. Similarly, hormone concentrations in breast adipose tissue were higher among women with ER?/PR? compared to ER-/PR-breast cancer, although differences were only significant for testosterone. These data demonstrate that high sex steroid concentrations in both serum and adipose tissues are more strongly related to ER?/PR? than ER-/PR-breast cancers. Measurement of sex hormones in serum and in the microenvironment may help in understanding the hormonal etiology of breast cancer, suggest methods for prevention, and have value in gauging treatment response and prognosis.
Introduction
Cumulative exposure of breast epithelium to elevated levels of sex steroid hormones is proposed to mediate many of the risk factors for postmenopausal breast cancer, including nulliparity, late age at first birth, early age at menarche and late age at menopause, obesity, use of hormone replacement therapy and elevated levels of circulating steroid hormones [1] [2] [3] [4] [5] [6] . Proposed mechanisms underlying this exposure include stimulating proliferation of breast epithelial cells, acting as a substrate for conversion into DNA-damaging metabolites and other mechanisms [7] [8] [9] [10] [11] [12] . Among postmenopausal women, most estrogens are produced via aromatization of androgens in adipose tissue, and data suggest that circulating hormone levels may not accurately reflect levels in the breast. Several studies of postmenopausal women demonstrate that estradiol (E 2 ) levels are higher in the breast compared with blood [7] . Others have shown higher aromatase activity in breast quadrants containing cancer than in uninvolved quadrants of the same breast [8, [13] [14] [15] , and higher concentrations of E 2 , the most biologically active estrogen, in tumor tissue than in adipose [9, 16, 17] or non-neoplastic tissue of the same breast [18] . These results are consistent with numerous reports pointing to the importance of the tumor microenvironment, including surrounding adipocytes, in facilitating the growth and progression of breast cancer, and argue that hormone levels within breast tissues may be most relevant for understanding their role in breast carcinogenesis.
A link between obesity, high levels of circulating estrogens and increased risk for hormone receptor positive breast cancer has been established [19] . Additionally, obese women have a poorer prognosis regardless of tumor hormone receptor status, often presenting with high grade tumors and distant metastases. The underlying mechanism is not clear, although likely involves alterations in estrogen metabolism, growth factor pathways, and/or inflammatory markers. Efforts to understand the biology of breast adipose tissue may provide some clues. Benign breast epithelium and breast cancer are typically intermixed with adipose tissue, which provides both a reservoir and local site of hormone metabolism that may be particularly relevant for breast carcinogenesis in postmenopausal women. As women age, the breast undergoes progressive fatty replacement, and as this process is enhanced by obesity, the prevalence of women with predominantly fatty breasts has increased. Further, the metabolic and endocrine properties of adipose tissue differ between lean and obese women, and vary by body site, with fat in breasts of normal obese women and in tissue surrounding breast cancers exhibiting increased aromatase activity [19] . Thus, studying the hormonal properties of breast adipose may provide insights into the pathogenesis of estrogen receptor positive breast cancer, as well as the response to treatment or prevention with endocrine-based strategies [20] .
Previously, we validated a method for reliably measuring steroid hormone concentrations in breast adipose tissue [21] . Herein, we used this methodology to compare within person hormone levels in breast adipose tissue and serum from breast cancer cases who participated in a populationbased case-control study. For comparison, we measured hormone levels in serum from matched controls. Given data demonstrating that hormone receptor status defines clinically and etiologically distinct forms of breast cancer [22, 23] , our aim was to evaluate whether levels of circulating and adipose hormones differed in women with ER?/ PR? compared to ER-/PR-disease. To avert complexities related to fluctuation in circulating hormones with menstrual cycling, we restricted the study to postmenopausal women.
Materials and methods

Study design
The Polish Women's Health Study has been described in detail elsewhere [24] . Briefly, case subjects were women aged 20-74 years with pathologically confirmed breast cancer who resided in Warsaw or Łódź Poland from 2000 to 2003. Cases were identified through a rapid identification system in five institutions (*90% of cases) and cancer registries. Randomly identified population controls were frequency matched to cases by city and age in 5-year categories. The study included 2,386 cases (79% of eligible) and 2,502 controls (69% of eligible). Informed consent was provided as required by the National Cancer Institute and Institutional Review Boards in Poland.
Information on breast cancer risk factors was obtained through a personal interview as described elsewhere [24] . Women who were menstruating at the time of interview were considered premenopausal, those whose periods had stopped for 12 months or more were classified as postmenopausal, and women who began using hormone replacement therapy while still menstruating were considered to have undefined menstrual status. BMI was calculated from measured weight and standing height (kg/m 2 ) from *95% of subjects and estimated from self-reported information for the remainder. Information related to tumor pathology was obtained from medical records, including results for estrogen receptor (ER) and progesterone receptor (PR). Selected histologic slides were reviewed by the study pathologist (M.E.S.) to confirm tumor type and grade. For tumors with available study blocks, we repeated ER and PR immunohistochemical analyses, which yielded results that were highly correlated with those in the medical record [25] .
Subject selection and tissue collection
The main aim of this study was designed to compare intraindividual hormone levels in breast adipose tissue and serum in relationship to hormone receptor status among breast cancer cases. We restricted cases to postmenopausal women residing in Warsaw who were not current users of exogenous hormones and who provided blood and frozen breast tissues (tumor and non-tumor) prior to treatment. ER/PR status was determined from hospital records. In the entire case-control study, there were 248 case subjects in Warsaw who provided blood and frozen tissues. Of these, 168 were postmenopausal at the time of surgery, including 79 ER?/PR? cases, 3 ER-/PR?, 28 ER?/PR-, 41 ER-/ PR-, and 17 with unknown receptor status based on medical records. Given that most tumors are ER?/PR? or ER-/PR-, we restricted cases to these subtypes, and selected 69 ER?/PR? (87% of available cases) and 31 (76%) of available ER-/PR-cases for study. Fresh tissue samples of adipose tissue were collected following surgery, snap frozen in liquid nitrogen and stored at -80°C. Adipose tissue was selected if it was grossly free of tumor, contained minimal non-fatty tissue and was free of blood.
Although this analysis focused on the intra-individual comparison of hormone concentrations in adipose tissue and serum among cases, we also assessed serum levels among controls for comparison with cases. Controls were frequency matched to cases by age at case diagnosis (±2 years), residence, age at menopause (±2 years) and were not currently using hormone supplements.
Laboratory methods
Methods to measure steroid hormones in breast adipose tissue have been reported [21] . Briefly, we separated oil from the more dense stromal cells by flotation. The minced breast adipose tissue was incubated with 1 ml of 1 mg/ml collagenase (type 1A; Sigma Chemical Co., St Louis, MO) in Krebs-Ringer bicarbonate buffer (4% w/v BSA) (Sigma Chemical Co., St. Louis, Mo) at 37°C for 50 min in a shaking water bath. The floating oil layer was separated by centrifugation. Purification steps were undertaken prior to quantifying the following steroid hormones by RIA: E 1 , E 2 , A, and T. The tritiated forms of these steroids were used to follow procedural losses. They were added to the oil and incubated at 50°C for 10 min. The steroids were then extracted from the oil and subsequently redissolved in 1 ml of isooctane. The isooctane was transferred to a Celite partition chromatography column, and E 1 , E 2 , A, and T were eluted sequentially and quantified by RIA. Results are expressed per gram of oil. Adipose tissue samples were assayed in six batches. For quality control (QC) purposes, a single specimen of discarded breast adipose tissue was obtained at surgery and cut into six pieces of equivalent weight, one of which was included in each batch. Overall CVs were as follows: A (18%), T (29%), E 1 (19%), E 2 (26%) and detection limits were: 12.1, 12.1, 6.1, and 3.05 pg/g oil for A, T, E1, and E 2 , respectively. Serum samples were extracted and A, T, E 1 , and E 2 were separated by Celite column partition chromatography. E 1 S was quantified by direct RIA (Beckman-Coulter, Minneapolis, MN). Sex hormone-binding globulin (SHBG) was measured by chemiluminescent immunoassay on the Immulite 2000 System analyzer (Siemens Healthcare Diagnostics, Deerfield, IL). Overall CVs were as follows: A, 10.2%; T, 17.3%; E 1 , 12.5%; E 2 , 22.7%; E 1 S, 6.5%; SHBG, 7.4%. The detection limits were: 40, 20, 4, 1, and 250 pg/ml for A, T, E 1 , E 2 , and E 1 S, respectively, and 8 nmol/l for SHBG.
Statistical methods
The main analysis compared hormone levels in breast adipose tissue and serum of individual case subjects (within subject comparison). We also assessed serum hormone levels among controls. Levels of all hormones and SHBG were transformed to the natural logarithm scale to normalize distributions. Differences in baseline characteristics between cases and controls were compared using the t test for continuous variables, Pearson's correlation coefficient, and the v 2 test for categorical variables. Casecontrol differences and case-case differences in geometric mean hormone concentrations by hormone receptor subgroup were evaluated by analysis of covariance with adjustment for age at specimen collection, age at menopause, and BMI. Further adjustment for known breast cancer risk factors, including parity, age at menarche, prior supplemental hormone, and prior oral contraceptive use did not alter findings and were not included in the final models. Analyses were conducted using SYSTAT software package, Version 12 [26] . Table 1 presents the distribution of selected demographic characteristics and breast cancer risk factors by case-control status and hormone receptor subgroup. The frequency distribution of most risk factors was similar between ER/PR ?/? and ER/PR -/-women, although the latter were more likely to have had a full-term pregnancy (89.7% of ER-/PR-women vs. 82.9% of ER/PR ?/? women) and a history of self-reported benign breast disease (25 vs. 13.2%). BMI was slightly higher among ER-/PR-cases (29.5 vs. 28.4 in ER?/PR? women). Compared to controls, cases overall were more likely to be nulliparous (15% of cases vs. 10% of controls), report a history of breast cancer in a first degree relative (16.1% of cases, 13% of controls) and a prior diagnosis of benign breast disease (16.7% cases, 9.1% controls).
Results
Characteristics of subjects
Adipose tissue hormone levels
Case-case comparisons demonstrated that unadjusted concentrations of the four hormones measured in breast adipose tissue were higher among women with ER?/PR? breast cancer as compared to women with ER-/PRtumors (Table 2) , despite BMI being higher in the latter group. E 1 S was not detected in adipose samples. After adjustment for age, BMI, age at menopause, and serum concentration of the respective hormone, the largest and only significant difference between the case groups was found for T, which was almost 40% higher in women with ER?/PR? compared to ER-/PR-tumors (P = 0.002). It is notable that despite differences in the absolute levels, the relative concentrations of the adipose hormones were similar in both case groups. For instance, levels of A were approximately 17 times that of E 1 , while T was fourfold higher than E 2 , irrespective of receptor status.
Serum hormone levels
Women with ER?/PR? breast cancers had higher circulating levels of all measured sex steroid hormones and lower SHBG concentrations than women with ER-/PR-breast cancers or controls (Table 3) . Differences were for the most part modest, and not significant. For the cases, the greatest disparities were in A, E 1 S, and SHBG, with women with ER?/PR? tumors having 24% higher levels than A, (P = 0.526); 20% higher E 1 S (P = 0.132); and 20% lower SHBG (P = 0.088). Concentrations of serum sex hormones did not vary significantly between controls and all cases combined. Adjustment for age at blood draw, BMI and age at menopause had little effect on these findings.
Similar to results for hormone levels in the adipose, the relative concentrations of serum hormones did not differ by receptor status. However, in contrast to adipose tissue where T was fourfold higher than E 2 , in serum, T was nearly 30 times higher than E 2 for both ER-/PR? and ER-/PR-women. Although using a different metric, levels of most of the hormones in adipose were approximately 10 times greater than those in serum for both hormone receptor-defined groups of women. The notable exception was the relatively high concentration of T in serum which resulted in comparable levels in serum and adipose. Figure 1a -d plots serum and adipose tissue hormone concentrations by ER/PR status. Among ER?/PR? women, adipose hormones were highly correlated with circulating levels; Pearson's correlation coefficients were statistically significant and ranged from 0.57 for T to 0.84 for A. For ER-/PR-women, correlations were weaker (ranging from 0.35 for E 2 to 0.75 for E 1 ), but nonetheless significant for all blood/adipose tissue comparisons except E 2 . Women with both high serum and adipose T tended to be overwhelmingly ER?/PR?.
BMI influence on serum and adipose hormones
As expected, levels of T, E 1 , and E 2 in adipose tissue, and to a lesser degree in serum, rose with increasing BMI. a For all serum sex hormones, geometric means adjusted for age at blood collection (continuous), age at menopause (continuous) and BMI (continuous) are presented. Concentrations are expressed as pg/ml, except for SHBG, which is expressed in nmol/l. Free E 2 is the percent of unbound E 2 * P value for test of differences in means between cancer subtypes (Table 4) .
Discussion
This study suggests that analysis of breast adipose tissue may enhance our understanding of the hormonal etiology of breast cancer. Our data demonstrate that hormone levels are higher in serum and breast adipose tissues of postmenopausal women with ER?/PR? breast cancers as compared to those with ER-/PR-tumors. In addition, although levels in serum and fat were correlated, measurements of adipose tissue were more strongly correlated with receptor status than serum concentrations, particularly for T. Nonetheless, the ratio of T to E 2 in fat was lower than in serum, suggesting that adipose tissue represents a reservoir of androgens that are actively converted to estrogens in breasts containing cancer. Notably, the subset of women who had the highest levels of T in both serum and adipose tissue included a preponderance of ER?/PR? cancers. Thus, our findings provide additional evidence for the importance of T in postmenopausal ER?/PR? breast cancer [27] and extend findings demonstrating etiological differences between hormone receptor positive and negative tumors. Our findings also suggest that obesity may be related to increased E 2 production in the breast among postmenopausal cancer patients. Specifically, we found that elevated BMI is related to higher levels of T in breast fat, thus providing a substrate for estrogen synthesis. In turn, elevated E 2 in the breast may lead to breast cancer progression or heightened aggressiveness by driving proliferation or through other mechanisms. Consistent with this view, recent studies in mice and in clinical studies found that diet-induced obesity results in inflammatory lesions within the breast, leading to elevated aromatase expression [28] . Activation of aromatase in the breast could account for our observation that the ratio of T to E 2 is lower in adipose tissues than in blood. Furthermore, expression of ER by cancer cells may lead to accumulation of E 2 in tumor tissue, thereby diminishing levels in fat. The translational importance of hormone metabolism in the breast adipose remains unclear. Although obesity is linked to a poorer prognosis for breast cancer, data are inconsistent as to whether elevated BMI reduces the effectiveness of antihormonal agents [29] and whether low mammographic density (reflecting a high percentage of breast fat) is associated with a worse prognosis independent of BMI.
Previous studies of sex hormone concentrations in breast tissue, particularly adipose, are limited in number and in size, and have focused mainly on measurement of estrogens. [7, [16] [17] [18] [30] [31] [32] [33] [34] [35] . Data generally indicate that [35] E 2 concentrations in breast tumor tissues are higher than in the surrounding non-neoplastic tissues, independent of menopausal status. In contrast, E 1 tends to be lower in neoplastic than in the surrounding tissues, perhaps reflecting its favored conversion to E 2 . Limited data [36, 37] suggest that dehydroepiandrosterone and A are lower, while T is comparable in breast tumors compared with the surrounding tissue [35] . Although E 1 S is abundant in serum, it was undetectable in breast fat using our methods, presumably because of its high polarity and low fat solubility. Overall, our findings and previous studies suggest that androgen and estrogen levels are higher in breast tissues and blood of women with ER? as compared with ER-breast cancers [30, 38] .
Our approach differs from previous studies with regard to technical issues and patient selection. Most previous studies analyzed adipose tissue samples identified by visual inspection and expressed hormone concentrations per gram of specimen or protein content, whereas we digested tissues prior to assaying and expressed concentrations per gram of oil. In addition, differences in sensitivity and precision of RIAs [39] may affect comparisons across studies. By including purification steps to remove potential interfering compounds prior to applying the RIAs, we achieved adequate precision, as evidenced by CVs below 20% for all analytes measured. However, CVs for the adipose tissue hormone assays were higher; probably reflecting additional variability arising from differences in the cellular composition of the samples. Despite these concerns, we are encouraged that the absolute levels of circulating estrogens and androgens in this study are similar to values reported in recent studies [10, 30] . Improving assay methods, including a shift to mass spectrometry assays, is a subject of much ongoing investigation [30, 39] .
Our finding of high correlations between adipose and serum hormones, with lower levels consistently observed in ER-/PR-women, argues that the uptake of steroids from the circulation is a primary contributor to breast adipose hormone content. However, hormone metabolism in the breast may lead to changes in local concentrations that are not evident in blood. A limitation of most studies including ours is that we studied women with prevalent invasive breast cancer, where the sequestration, synthesis and catabolism of hormones within the tumor may affect levels measured in associated non-neoplastic tissue or in serum. A more comprehensive understanding of the interrelationships of these hormones would require testing levels in several tissues and serum simultaneously in breast cancer cases and cancer-free women. Studying these complex relationships will help to refine our understanding of breast cancer etiology and could potentially suggest methods for prevention and management.
